Document Detail


Hypertension increases cerebral 6-18F-fluorodopa-derived radioactivity.
MedLine Citation:
PMID:  19690020     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
6-(18)F-fluorodopa PET depicts the striatal dopaminergic lesion characterizing Parkinson disease (PD); however, striatal uptake of 6-(18)F-fluorodopa-derived radioactivity can be normal. Supine hypertension (SH) might increase 6-(18)F-fluorodopa uptake. METHODS: We measured putamen, caudate, and occipital cortex 6-(18)F-fluorodopa-derived radioactivity and supine blood pressure in patients with PD + SH (systolic pressure >/= 180 mm Hg, n = 8), patients with PD without SH (PD - SH, n = 19), patients with pure autonomic failure (n = 8), and controls (n = 16). RESULTS: Peak putamen radioactivity correlated with supine systolic pressure across all subjects and among PD patients and was higher in PD + SH than in PD - SH (P = 0.01). Both subgroups had rapid fractional declines in radioactivity between the peak and late values (P < 0.0001, compared with controls). Arterial 6-(18)F-fluorodopa concentrations were similar in the compared groups. CONCLUSION: In PD, SH is associated with augmented striatal 6-(18)F-fluorodopa-derived radioactivity. Regardless of SH, retention of 6-(18)F-fluorodopa-derived radioactivity is markedly reduced. A model-independent approach can identify striatal dopaminergic denervation in PD.
Authors:
David S Goldstein; Courtney Holmes; Latoya Sewell; Irwin J Kopin
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2009-08-18
Journal Detail:
Title:  Journal of nuclear medicine : official publication, Society of Nuclear Medicine     Volume:  50     ISSN:  0161-5505     ISO Abbreviation:  J. Nucl. Med.     Publication Date:  2009 Sep 
Date Detail:
Created Date:  2009-08-28     Completed Date:  2009-10-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0217410     Medline TA:  J Nucl Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1479-82     Citation Subset:  IM    
Affiliation:
Clinical Neurocardiology Section, Clinical Neurosciences Program, Division of Intramural Research, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA. goldstein@ninds.nih.gov
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Brain / metabolism*,  radionuclide imaging
Dihydroxyphenylalanine / analogs & derivatives*,  diagnostic use,  pharmacokinetics
Female
Humans
Hypertension / complications,  metabolism*,  radionuclide imaging
Male
Metabolic Clearance Rate
Middle Aged
Parkinson Disease / complications,  metabolism*,  radionuclide imaging
Radiopharmaceuticals / diagnostic use,  pharmacokinetics
Tissue Distribution
Chemical
Reg. No./Substance:
0/Radiopharmaceuticals; 63-84-3/Dihydroxyphenylalanine; 75290-51-6/fluorodopa F 18

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Automated quality control for segmentation of myocardial perfusion SPECT.
Next Document:  Optimization of the Injected Activity in Dynamic 3D PET: A Generalized Approach Using Patient-Specif...